FDA Clearance Tracker · P210006
Thoraflex Hybrid
Last checked: Nov 20, 2026Latest source record: Apr 19, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Apr 19, 2022
Approved
Time to decision
418 days
Received Feb 25, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P210006
- Device name
- Thoraflex Hybrid
- Applicant
- Vascutek, Ltd.
- Applicant location
- Inchinnan
- Received
- Feb 25, 2021
- Decided
- Apr 19, 2022
- Decision
- Approved
- Supplements
- 18 in FDA's data for this PMA. See them on the FDA record
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for the Thoraflex Hybrid. The device is intended for the open surgical repair or replacement of damaged or diseased vessels of the aortic arch and descending aorta with or without involvement of the ascending aorta in cases of aneurysm and/or dissection.
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QSK (Hybrid stent graft, thoracic aortic lesion treatment).
- It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).
Source documents
Other decisions for Vascutek, Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K241550 · Decided Feb 27, 2025 · 272 days after receipt
Device type: Prosthesis, Vascular Graft, Of 6mm And Greater Diameter (DSY) · Cardiology
K241070 · Decided Nov 15, 2024 · 210 days after receipt
Device type: Prosthesis, Vascular Graft, Of 6mm And Greater Diameter (DSY) · Cardiology
K202703 · Decided Apr 6, 2021 · 202 days after receipt
Device type: Prosthesis, Vascular Graft, Of 6mm And Greater Diameter (DSY) · Cardiology
3 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.